Aptinyx discovers and develops
innovative therapies for
challenging disorders of the brain and
nervous system.

nerve 650

Aptinyx's proprietary compounds modulate
the NMDA receptor,
a critical regulator
involved in nerve cell
communication.

Aptinyx seeks to leverage its experience and
track record of success to rapidly advance promising therapies in development for patients in need.

About Aptinyx

Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of transformative therapies for challenging neurologic disorders. Aptinyx has a proven platform for discovering compounds that work through a novel mechanism: modulation of the NMDA receptor to enhance pathways involved with nerve cell communication.

Learn more about Aptinyx »

Latest News

March 21, 2018
Aptinyx to Present at Needham & Company’s 17th Annual Healthcare Conference(pdf)

March 15, 2018
Aptinyx Presents Data on NMDA Receptor Modulator NYX-458 in a Preclinical Model of Parkinson’s Cognitive Impairment at the AAT-AD/PD Focus Meeting 2018(pdf)

March 12, 2018
Aptinyx to Present at 38th Annual Cowen Health Care Conference(pdf)

See all press and news »